Severe Acute Respiratory Syndrome (SARS)
SARS-1 originated in southern China in November 2002 and was brought to Hong Kong in February 2003. From Hong Kong, the disease spread rapidly worldwide but primarily to Asian countries. At the end of the SARS-1 epidemic in 2004, the global cumulative total was 8,422 cases with 916 deaths (case fatality rate of 11%).
SARS-1 is a different coronavirus than the SARS-CoV-2, which the WHO identified in 2019. The new coronavirus is inferred as an order of magnitude more infectious than its forerunner SARS-CoV-1, consistent with the pandemic status achieved by COVID-19.
As of November 5, 2021, the U.S. FDA had not Approved or Authorized a SARS-1 vaccine.
SARS-CoV Outbreak Timeline
2003 - SARS was first reported in Asia in February and became a notifiable disease in mid-April China. As of July 2003, the WHO reported 325 cases, and the illness spread to about 24 countries in North America, South America, Europe, and Asia 2003.
2003 - SARS has not re-emerged naturally, but there have been 6 escapes from virology labs: 1 event each in Singapore and Taiwan, and 4 separate escapes of the coronavirus at the same laboratory in Beijing, China.
2004 - The WHO published during October the 'SARS Risk Assessment and Preparedness Framework.' And, the CDC issues “Notice of Embargo of Civets.” A SARS-like virus had been isolated from civets (captured in China's areas where the SARS outbreak originated). As a result, CDC banned the importation of civets, which remains in effect.
2005 - A pre-clinical study finds chloroquine effectively inhibits SARS CoV infection and spread in cell culture. Similar studies describe these proteins' roles in SARS-CoV replication and potential therapeutic strategies to prevent SARS-CoV entry into target cells.
2005 - Microbiologist Kwok-yung Yuen of the University of Hong Kong and colleagues sampled monkeys, rodents, and bat species in Hong Kong's hinterlands. The SARS-like virus was found in 39% of the anal swabs collected from Chinese horseshoe bats, both eaten and used in traditional Chinese medicine. Also, around 80% of serum samples collected from the bats showed antibodies to the virus.
From 2007-17, there were two dozen incidents at US-based labs involving influenza, SARS, and MERS, according to documents obtained through the Freedom of Information Act by Lynn Klotz, a senior science fellow at the Center for Arms Control and Non-Proliferation, and shared with the Monitor. Ten of those incidents occurred at UNC-Chapel Hill, all involving SARS and featuring a range of scenarios.
In November 2015, the journal Nature published a study: 'A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Furthermore, the study abstract stated, 'Our work suggests a potential risk of SARS-CoV re-emergence from viruses currently circulating in bat populations.'
An Editors’ Note added in March 2020 stated: 'We are aware that this article is being used as the basis for unverified theories that the novel coronavirus causing COVID-19 was engineered. There is no evidence that this is true; scientists believe that an animal is the most likely source of the coronavirus.'
“In China, the last six known outbreaks of SARS-1 have been out of labs, including the last known outbreak,” said Dr. Scott Gottlieb, the former commissioner of the Food and Drug Administration, on CBS’s “Face the Nation" on May 30, 2021.
Human coronavirus was initially cultured in the 1960s from nasal cavities of people with the common cold, reports a recent study. They are the 2nd leading cause of the common cold after rhinoviruseAccording to the CDC, people worldwide commonly get infected with human coronaviruses 229E, NL63, OC43, and HCDC. The discovery of bat SARS-like coronaviruses and the great genetic diversity of coronaviruses in bats have shed new light on SARS coronaviruses' origin and transmission.
There are four main sub-groupings of coronaviruses, known as alpha, beta, gamma, and delta. SARS-CoV is a betacoronavirus, like MERS.
The incubation period for SARS is typically 2 to 7 days, although it may be as long as 10 days in some cases. In a tiny proportion of patients, incubation periods of up to 14 days have been reported. The WHO estimates that the SARS case fatality ratio ranges from 0% to 50%, depending on the age group affected.
During the SARS outbreak in 2004 in China, SARS-CoV RNA was detected in 100% of untreated and 30% of disinfected wastewater samples collected from a hospital in Beijing, China receiving SARS patients (Wang et al., 2005).
The U.S. CDC published a report in December 2006 that concluded 'Bats have been identified as a natural reservoir for an increasing number of emerging zoonotic viruses, including henipaviruses and variants of rabies viruses. Recently, another group independently identified several horseshoe bat species as the reservoir host for many viruses with a close genetic relationship with the coronavirus associated with severe SARS. In addition to SARS-like coronaviruses, many other novel bat coronaviruses, which belong to groups 1 and 2 of the 3 existing coronavirus groups, have been detected by PCR.
A study published in 2015 suggest that convalescent plasma may have a clinically relevant impact in reducing the rate of mortality and viral load in patients with SARI of viral etiology. Post hoc pooled meta-analysis across all viral etiologies showed a statistically significant 75% reduction in the odds of mortality among those treated with convalescent plasma or serum. In addition, we found no evidence of serious adverse events or complications due to therapy and limited evidence of a reduction in the use of critical care resources and the length of hospital stay.
A study published in 2014 summarized saying 'Convalescent plasma may reduce mortality and appears safe. However, this therapy should be studied within the context of a well-designed clinical trial or other formal evaluation, including for treatment of Middle East respiratory syndrome coronavirus CoV infection.'
A study published in 2005 found 'all infected healthcare workers whose SARS condition had progressed severely and who had failed to respond to the available treatment, survived after transfusion with convalescent plasma.
A 2015 study suggests a potential risk of SARS-CoV re-emergence from viruses currently circulating in bat populations. The results indicate that group 2b viruses encoding the SHC014 spike in a wild-type backbone can efficiently use multiple orthologs of the SARS receptor human angiotensin-converting enzyme II (ACE2), replicate efficiently in primary human airway cells, and achieve in vitro titers equivalent to epidemic strains of SARS-CoV.
A study published in 2007 found horseshoe bats are the natural reservoir for the SARS-CoV-like virus. Civets are the amplification host, highlighting the importance of wildlife and biosecurity in farms and wet markets, serving as the source and amplification centers for emerging infections.
NOTE: This page's content is sourced from the CDC, WHO, clinicaltrials.gov, and the Precision Vax news network. This information was last fact-checked by healthcare providers, such as Dr. Robert Carlson.